GlassScriptPhysician profile
Harvey Dosik
NPI 1891747655
$4,671.05
in general payments reported to CMS, 2019-2025
47 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $426 · 2021: $491 · 2022: $534 · 2023: $498 · 2024: $493 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $582.46 | 2019-2025 | |
| Daiichi Sankyo INC. | $338.19 | 2019-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $308.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $278.23 | 2019-2023 | Keytruda |
| Incyte Corporation | $270.32 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Alexion Pharmaceuticals, INC. | $268.39 | 2019 | |
| Gilead Sciences, INC. | $194.51 | 2019-2025 | Trodelvy |
| Celltrion USA INC. | $176.55 | 2023-2025 | Vegzelma |
| Janssen Biotech, INC. | $135.24 | 2019-2025 | Darzalex, Tecvayli |
| Abbvie INC. | $123.86 | 2024-2025 | |
| Taiho Oncology, INC. | $122.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $120.54 | 2019-2022 | |
| Pfizer INC. | $117.52 | 2019-2023 | |
| Genzyme Corporation | $116.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $113.84 | 2022-2025 | Ojjaara, Blenrep |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Dosik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.